🇺🇸 Disc Medicine, Inc.IRON

Company Update Form 8-K 19-10-2026 07:08:08 EDT

Subject: 8-K Items 7.01, 8.01, 9.01

Overview: Announced topline results from the Phase 3 APOLLO trial of bitopertin, which met all primary and secondary endpoints for treating EPP and XLP.

Source: SEC EDGAR · Original filing

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest